Dr. Stephenson on the Development of Biomarkers for Prostate Cancer

Andrew J. Stephenson, MD
Published: Monday, Aug 21, 2017



Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
 


Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the development of biomarkers for patients with prostate cancer.

It is important to develop tools to predict how patients are going to react to treatments, explains Stephenson. This can help the patient’s quality of life and equip them with the knowledge to make a well-informed decision regarding their treatment. Additionally, this can lead to higher rates of patient satisfaction, states Stephenson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x